Transplacental transfer and metabolism of buprenorphine

Tatiana Nanovskaya, Sujal Deshmukh, Monica Brooks, Mahmoud Ahmed

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Information on the direct and indirect effects of buprenorphine (BUP) on the fetus is essential for determining its potential for treatment of the pregnant opiate addict. The goal of this investigation is to determine the transplacental transfer of BUP to the fetal circulation, its metabolism, and effects on the tissue. The technique of dual perfusion of placental lobule is used. The range of BUP concentrations investigated included its peak plasma levels (10 ng/ml) in patients under treatment. A biphasic decline in concentration of the drug in the maternal circulation was observed, initially rapid then slow. During the initial (60 min), the tissue sequestered most of BUP resulting in a low (<10%) transplacental transfer of the drug to the fetal circulation. The concentration ratios of the drug in tissue/maternal and tissue/fetal were 13 ± 6.5 and 27.4 ± 0.4. The drug sequestered did not have any adverse effects on placental tissue viability and functional parameters. Less than 5% of the perfused BUP was metabolized to norbuprenorphine during the 4 h of perfusion and the metabolite was distributed between the tissue, maternal, and fetal circulations. Taken together, these data suggest that the therapeutic levels of BUP in the maternal circulation may have no indirect effects (via the placenta) on the fetus. The observed low transplacental transfer of BUP to the fetal circuit may explain the moderate/absence of neonatal withdrawal in the limited number of reports on mothers treated with the drug during pregnancy.

Original languageEnglish (US)
Pages (from-to)26-33
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume300
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Buprenorphine
Mothers
Fetus
Pharmaceutical Preparations
Opiate Alkaloids
Perfusion
Tissue Survival
Placenta
Therapeutics
Pregnancy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Transplacental transfer and metabolism of buprenorphine. / Nanovskaya, Tatiana; Deshmukh, Sujal; Brooks, Monica; Ahmed, Mahmoud.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 300, No. 1, 2002, p. 26-33.

Research output: Contribution to journalArticle

@article{c52f2efc874d45eabd5534dd1c7a5148,
title = "Transplacental transfer and metabolism of buprenorphine",
abstract = "Information on the direct and indirect effects of buprenorphine (BUP) on the fetus is essential for determining its potential for treatment of the pregnant opiate addict. The goal of this investigation is to determine the transplacental transfer of BUP to the fetal circulation, its metabolism, and effects on the tissue. The technique of dual perfusion of placental lobule is used. The range of BUP concentrations investigated included its peak plasma levels (10 ng/ml) in patients under treatment. A biphasic decline in concentration of the drug in the maternal circulation was observed, initially rapid then slow. During the initial (60 min), the tissue sequestered most of BUP resulting in a low (<10{\%}) transplacental transfer of the drug to the fetal circulation. The concentration ratios of the drug in tissue/maternal and tissue/fetal were 13 ± 6.5 and 27.4 ± 0.4. The drug sequestered did not have any adverse effects on placental tissue viability and functional parameters. Less than 5{\%} of the perfused BUP was metabolized to norbuprenorphine during the 4 h of perfusion and the metabolite was distributed between the tissue, maternal, and fetal circulations. Taken together, these data suggest that the therapeutic levels of BUP in the maternal circulation may have no indirect effects (via the placenta) on the fetus. The observed low transplacental transfer of BUP to the fetal circuit may explain the moderate/absence of neonatal withdrawal in the limited number of reports on mothers treated with the drug during pregnancy.",
author = "Tatiana Nanovskaya and Sujal Deshmukh and Monica Brooks and Mahmoud Ahmed",
year = "2002",
doi = "10.1124/jpet.300.1.26",
language = "English (US)",
volume = "300",
pages = "26--33",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Transplacental transfer and metabolism of buprenorphine

AU - Nanovskaya, Tatiana

AU - Deshmukh, Sujal

AU - Brooks, Monica

AU - Ahmed, Mahmoud

PY - 2002

Y1 - 2002

N2 - Information on the direct and indirect effects of buprenorphine (BUP) on the fetus is essential for determining its potential for treatment of the pregnant opiate addict. The goal of this investigation is to determine the transplacental transfer of BUP to the fetal circulation, its metabolism, and effects on the tissue. The technique of dual perfusion of placental lobule is used. The range of BUP concentrations investigated included its peak plasma levels (10 ng/ml) in patients under treatment. A biphasic decline in concentration of the drug in the maternal circulation was observed, initially rapid then slow. During the initial (60 min), the tissue sequestered most of BUP resulting in a low (<10%) transplacental transfer of the drug to the fetal circulation. The concentration ratios of the drug in tissue/maternal and tissue/fetal were 13 ± 6.5 and 27.4 ± 0.4. The drug sequestered did not have any adverse effects on placental tissue viability and functional parameters. Less than 5% of the perfused BUP was metabolized to norbuprenorphine during the 4 h of perfusion and the metabolite was distributed between the tissue, maternal, and fetal circulations. Taken together, these data suggest that the therapeutic levels of BUP in the maternal circulation may have no indirect effects (via the placenta) on the fetus. The observed low transplacental transfer of BUP to the fetal circuit may explain the moderate/absence of neonatal withdrawal in the limited number of reports on mothers treated with the drug during pregnancy.

AB - Information on the direct and indirect effects of buprenorphine (BUP) on the fetus is essential for determining its potential for treatment of the pregnant opiate addict. The goal of this investigation is to determine the transplacental transfer of BUP to the fetal circulation, its metabolism, and effects on the tissue. The technique of dual perfusion of placental lobule is used. The range of BUP concentrations investigated included its peak plasma levels (10 ng/ml) in patients under treatment. A biphasic decline in concentration of the drug in the maternal circulation was observed, initially rapid then slow. During the initial (60 min), the tissue sequestered most of BUP resulting in a low (<10%) transplacental transfer of the drug to the fetal circulation. The concentration ratios of the drug in tissue/maternal and tissue/fetal were 13 ± 6.5 and 27.4 ± 0.4. The drug sequestered did not have any adverse effects on placental tissue viability and functional parameters. Less than 5% of the perfused BUP was metabolized to norbuprenorphine during the 4 h of perfusion and the metabolite was distributed between the tissue, maternal, and fetal circulations. Taken together, these data suggest that the therapeutic levels of BUP in the maternal circulation may have no indirect effects (via the placenta) on the fetus. The observed low transplacental transfer of BUP to the fetal circuit may explain the moderate/absence of neonatal withdrawal in the limited number of reports on mothers treated with the drug during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=0036137057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036137057&partnerID=8YFLogxK

U2 - 10.1124/jpet.300.1.26

DO - 10.1124/jpet.300.1.26

M3 - Article

VL - 300

SP - 26

EP - 33

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -